Division of Orgenesis Inc.
Latest From MaSTherCell SA
Already partnered with Oxford Nanopore through its acquisition of deCODE Genetics, Amgen invests in the UK biotech to enhance its genomic capabilities. Aclaris licenses dermatology product Rhofade from Allergan. Other recent licensing and alliance deals...
Helped by a new partnership with Belgium-based MaSTherCell, the South Korean biotech is aiming to initially challenge the European market with a stem cell therapy for atopic dermatitis, derived from human umbilical cord blood.
In Q1 2015 start-ups raised $2.74 billion, a new record. Biopharma companies penned 37 alliances; 13 start-ups were acquired across all industries.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced March 2015.
- Gene Therapy, Cell Therapy
- Contract Research, Toxicology Testing-CRO
- Therapeutic Areas
- Western Europe
- Parent & Subsidiaries
- Orgenesis Inc.
- Senior Management
Eric Mathieu, Operations
Patrick Stragier, Business
- Contact Info
Phone: 71 34 76 29
48, Rue Auguste Piccard
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.